TR201818988T4 - Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler. - Google Patents

Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler. Download PDF

Info

Publication number
TR201818988T4
TR201818988T4 TR2018/18988T TR201818988T TR201818988T4 TR 201818988 T4 TR201818988 T4 TR 201818988T4 TR 2018/18988 T TR2018/18988 T TR 2018/18988T TR 201818988 T TR201818988 T TR 201818988T TR 201818988 T4 TR201818988 T4 TR 201818988T4
Authority
TR
Turkey
Prior art keywords
multiple sclerosis
alleviating
symptoms
methods
compositions containing
Prior art date
Application number
TR2018/18988T
Other languages
English (en)
Inventor
Y Underwood Mark
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of TR201818988T4 publication Critical patent/TR201818988T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12005—Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)

Abstract

Buluş, bireyde, multipl skleroz ile ilişkili bir semptomun hafifletilmesinde kullanılmaya yönelik apoaequorin olup, apoaequorin ve bir taşıyıcı içeren bir oral doz olarak formüle edilen bir yöntem içerir.
TR2018/18988T 2012-09-27 2013-09-27 Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler. TR201818988T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261706615P 2012-09-27 2012-09-27

Publications (1)

Publication Number Publication Date
TR201818988T4 true TR201818988T4 (tr) 2019-01-21

Family

ID=50389004

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/18988T TR201818988T4 (tr) 2012-09-27 2013-09-27 Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler.

Country Status (24)

Country Link
US (1) US20150246101A1 (tr)
EP (1) EP2900253B1 (tr)
JP (1) JP6607782B2 (tr)
KR (1) KR102195761B1 (tr)
CN (1) CN104684566A (tr)
AU (1) AU2013323288B2 (tr)
BR (1) BR112015006755A2 (tr)
CA (1) CA2886097C (tr)
CY (1) CY1121216T1 (tr)
DK (1) DK2900253T3 (tr)
ES (1) ES2710937T3 (tr)
HK (1) HK1210698A1 (tr)
HR (1) HRP20190182T1 (tr)
HU (1) HUE041492T2 (tr)
IL (1) IL237751B (tr)
LT (1) LT2900253T (tr)
MX (1) MX369389B (tr)
PL (1) PL2900253T3 (tr)
PT (1) PT2900253T (tr)
SG (1) SG11201502418VA (tr)
SI (1) SI2900253T1 (tr)
TR (1) TR201818988T4 (tr)
WO (1) WO2014052807A1 (tr)
ZA (1) ZA201502849B (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
EP3515212A1 (en) * 2016-09-23 2019-07-31 Quincy Bioscience LLC Apoaequorin and vitamin d-containing compositions and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688417C (en) * 2007-05-24 2017-04-25 Calcimedica, Inc. Calcium channel proteins and uses thereof
WO2009114597A1 (en) * 2008-03-11 2009-09-17 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
CA2732757A1 (en) * 2008-08-06 2010-02-11 Merck Sharp & Dohme Corp. Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
WO2012022740A1 (en) * 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis

Also Published As

Publication number Publication date
ZA201502849B (en) 2016-07-27
CA2886097C (en) 2020-07-14
IL237751A0 (en) 2015-05-31
HK1210698A1 (en) 2016-05-06
CA2886097A1 (en) 2014-04-03
AU2013323288A1 (en) 2015-05-07
PL2900253T3 (pl) 2019-04-30
SG11201502418VA (en) 2015-04-29
DK2900253T3 (en) 2019-02-18
EP2900253B1 (en) 2018-11-14
JP6607782B2 (ja) 2019-11-20
HRP20190182T1 (hr) 2019-03-22
ES2710937T3 (es) 2019-04-29
MX369389B (es) 2019-11-07
MX2015003879A (es) 2015-07-17
SI2900253T1 (sl) 2019-03-29
PT2900253T (pt) 2019-02-25
AU2013323288B2 (en) 2017-12-07
KR20150060954A (ko) 2015-06-03
KR102195761B1 (ko) 2020-12-28
IL237751B (en) 2020-10-29
HUE041492T2 (hu) 2019-05-28
LT2900253T (lt) 2019-03-25
BR112015006755A2 (pt) 2017-07-04
US20150246101A1 (en) 2015-09-03
EP2900253A4 (en) 2016-06-15
CN104684566A (zh) 2015-06-03
CY1121216T1 (el) 2020-05-29
WO2014052807A1 (en) 2014-04-03
EP2900253A1 (en) 2015-08-05
JP2015532288A (ja) 2015-11-09

Similar Documents

Publication Publication Date Title
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
GB201106750D0 (en) Novel compounds
IN2015DN03795A (tr)
EP2870583A4 (en) GENERATION OF EVENTS OF SOCIAL GROUPS
IN2015DN03029A (tr)
IN2015DN00127A (tr)
AU342216S (en) Electric toothbrush
MX2014014970A (es) Recordatorios de deteccion de ubicacion.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
JO3154B1 (ar) عوامل مضادة لـ trpv4
PH12014501032A1 (en) 2-thiopyrimidinones
MX2015008813A (es) Composiciones y metodos para contrarrestar la inhibicion del factor xa.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
IN2014DN08412A (tr)
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
MX2016008209A (es) Composiciones y metodos para el cuidado oral.
IN2014DN07103A (tr)
PH12015501390A1 (en) Tablets with improved acceptance and good storage stability
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
TR201818988T4 (tr) Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler.
MX354872B (es) Composiciones para cuidado oral y metodos.
IN2015DN00962A (tr)
IN2014DN03298A (tr)